Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $3.36 in the prior trading day, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) closed at $2.76, down -17.86%. In other words, the price has decreased by -$17.86 from its previous closing price. On the day, 4.67 million shares were traded. PHAT stock price reached its highest trading level at $3.395 during the session, while it also had its lowest trading level at $2.71.
Ratios:
Our goal is to gain a better understanding of PHAT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 07 ’25 when Henderson Molly sold 3,678 shares for $4.55 per share. The transaction valued at 16,740 led to the insider holds 89,868 shares of the business.
Parikh Asit bought 10,000 shares of PHAT for $44,200 on Mar 13 ’25. The Director now owns 85,500 shares after completing the transaction at $4.42 per share. On Jan 21 ’25, another insider, Henderson Molly, who serves as the CFO and CBO of the company, sold 6,583 shares for $6.59 each. As a result, the insider received 43,371 and left with 93,546 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 192686912 and an Enterprise Value of 545007936. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.35. Its current Enterprise Value per Revenue stands at 6.658 whereas that against EBITDA is -1.908.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.09, which has changed by -0.74538743 over the last 52 weeks, in comparison to a change of 0.09765589 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $19.71, while it has fallen to a 52-week low of $3.07. The 50-Day Moving Average of the stock is -45.22%, while the 200-Day Moving Average is calculated to be -72.81%.
Shares Statistics:
The stock has traded on average 1.27M shares per day over the past 3-months and 1811990 shares per day over the last 10 days, according to various share statistics. A total of 69.64M shares are outstanding, with a floating share count of 38.69M. Insiders hold about 44.45% of the company’s shares, while institutions hold 59.97% stake in the company. Shares short for PHAT as of 1744675200 were 11384551 with a Short Ratio of 8.98, compared to 1741910400 on 14355935. Therefore, it implies a Short% of Shares Outstanding of 11384551 and a Short% of Float of 27.32.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Phathom Pharmaceuticals Inc (PHAT) involves the perspectives of 4.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.7, with high estimates of -$0.45 and low estimates of -$0.96.
Analysts are recommending an EPS of between -$2.56 and -$3.36 for the fiscal current year, implying an average EPS of -$3.06. EPS for the following year is -$0.67, with 4.0 analysts recommending between $0.3 and -$2.32.
Revenue Estimates
7 analysts predict $35.73M in revenue for the current quarter. It ranges from a high estimate of $37M to a low estimate of $32.7M. As of the current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $7.32MFor the next quarter, 7 analysts are estimating revenue of $42.73M. There is a high estimate of $47.37M for the next quarter, whereas the lowest estimate is $37.4M.
A total of 8 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $169.84M, while the lowest revenue estimate was $146.9M, resulting in an average revenue estimate of $158.86M. In the same quarter a year ago, actual revenue was $55.25MBased on 8 analysts’ estimates, the company’s revenue will be $328.18M in the next fiscal year. The high estimate is $381.1M and the low estimate is $270M.
